Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Current commercial antidepressants worldwide are mainly developed according to the monoaminergic hypothesis of depression and have various limitations. Thus, exploring new antidepressants with better therapeutic efficacy and fewer adverse effects remain a hot topic in the field of neuropsychiatric research. Peroxisome proliferator-activated receptors (PPARs) have been demonstrated to closely participate in the pathophysiology of depression, and here we assume that lanifibranor, a novel pan-PPAR agonist for α, δ, and γ, may induce antidepressant-like actions by PPARs activation. In the present study, by using multiple methods, we found that intraperitoneal injection of lanifibranor significantly prevented chronic stress-induced depressive-like behaviors such as anhedonia, helplessness, and social avoidance in mice. Administration of lanifibranor also notably reversed the inhibitory effects of chronic stress on hippocampal PPARα, neurogenesis, and the brain-derived neurotrophic factor (BDNF) signaling cascade in mice. Lanifibranor treatment did not antagonize the decreasing effects of chronic stress on hippocampal PPARδ and PPARγ. The use of two pharmacological inhibitors of PPARα and the BDNF system (GW6471 and K252a), adeno-associated virus (AAV)-PPARα-short hairpin RNA (shRNA), and AAV-BDNF-shRNA fully blocked the antidepressant-like actions of lanifibranor in mouse models. Taken together, the results of this study confirm that lanifibranor may be developed as a new antidepressant in the future.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.biopha.2025.118406 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Repurposing glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of depression: A systematic review of preclinical, observational and clinical investigations.
Eur Neuropsychopharmacol
September 2025
Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada. Electronic address:
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), currently used for metabolic conditions, have demonstrated potential antidepressant effects via neuromodulatory pathways. This systematic review aims to provide evidence on the antidepressant effects of GLP-1 RAs and elucidate their underlying mechanism of action.
Methods: We examined studies that investigated the effect of GLP-1 RAs on depressive symptoms.
Spontaneous glutamate release activates mGluR signaling to drive rapid antidepressant responses.
Proc Natl Acad Sci U S A
September 2025
Vanderbilt Brain Institute, Vanderbilt University, Nashville, TN 37240.
Major depressive disorder affects millions worldwide, yet current treatments require prolonged administration. In contrast, ketamine produces rapid antidepressant effects by blocking spontaneous N-Methyl-D-Aspartate (NMDA) receptor signaling, which lifts the suppression of protein synthesis and triggers homeostatic synaptic plasticity. Here, we identify a parallel signaling pathway involving metabotropic glutamate receptor 5 (mGluR5) that promotes rapid antidepressant-like effects.
View Article and Find Full Text PDFPemafibrate treatment produces antidepressant-like effects in CUMS and CRS models through activation of hippocampal PPARa and BDNF signaling.
Int J Neuropsychopharmacol
August 2025
Department of Orthopedics, Affiliated Hospital 2 of Nantong University, Nantong 226000, Jiangsu, China.
Background: It is well established that peroxisome proliferator-activated receptor α (PPARα) plays a crucial role in the pathogenesis of depression. Several PPARα agonists, including WY14643, fenofibrate, and gemfibrozil, have been reported to produce antidepressant-like effects in mouse models through PPARα-mediated enhancement of hippocampal brain-derived neurotrophic factor (BDNF) signaling and neurogenesis. Pemafibrate is a novel and highly selective modulator of PPARα, and therefore, we hypothesised that it might also exhibit antidepressant-like efficacy.
View Article and Find Full Text PDFAntidepressant-like actions of lanifibranor and its related mechanisms in mouse models of depression: Involvement of hippocampal PPARα and BDNF.
Biomed Pharmacother
August 2025
Department of Psychiatry, The Fourth People's Hospital of Nantong, Nantong, Jiangsu 226000, China. Electronic address:
Current commercial antidepressants worldwide are mainly developed according to the monoaminergic hypothesis of depression and have various limitations. Thus, exploring new antidepressants with better therapeutic efficacy and fewer adverse effects remain a hot topic in the field of neuropsychiatric research. Peroxisome proliferator-activated receptors (PPARs) have been demonstrated to closely participate in the pathophysiology of depression, and here we assume that lanifibranor, a novel pan-PPAR agonist for α, δ, and γ, may induce antidepressant-like actions by PPARs activation.
View Article and Find Full Text PDFSalt-inducible kinase 1 and CREB-regulated transcription co-activator 1 in the paraventricular nucleus participate in the antidepressant-like mechanism of (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine in mice.
Neuropharmacology
November 2025
Office of Research and Innovation, The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, Luoyang, 471003, Henan, China. Electronic address:
Background: Previous studies have demonstrated that ketamine's metabolic conversion to (2S, 6S; 2R, 6R)-HNK is indispensable for its fast-onset and long-lasting antidepressant-like actions, and moreover, both (2R, 6R)-HNK and (2S, 6S)-HNK exert N-methyl-D-aspartate receptor (NMDAR)-independent antidepressant-like activities. Up to date, many pharmacological targets other than NMDAR have been reported for (2R, 6R)-HNK and (2S, 6S)-HNK. We have previously found that salt-inducible kinase 1 (SIK1) and cAMP response element binding protein (CREB)-regulated transcription co-activator 1 (CRTC1) in the paraventricular nucleus (PVN) participate in depression neurobiology by regulating the hypothalamic-pituitary-adrenal (HPA) axis, and here, we assume that (2R, 6R)-HNK and (2S, 6S)-HNK may also produce effects on the two molecules.
View Article and Find Full Text PDF